TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20732372
Drug: Aripiprazole (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (5-20 mg/day for 8 weeks)
Study: 20732372
Drug: Benzamide antipsychotics
Normalized name: Benzamide antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzamide antipsychotics (amisulpride and sulpiride)
Study: 20739388
Drug: motesanib 125
Normalized name: Motesanib
DrugBank: Motesanib (DB05575)
Approvals — FDA: no, EMA: no, PMDA: no
Description: motesanib 125 mg once daily for up to 48 weeks
Study: 20797845
Drug: L19-IL2 (22.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L19-IL2 (22.5 Mio IU IL2 equivalent dose)
Study: 20798939
Drug: Docetaxel (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (80 mg/m2 as a 1-h infusion in a 21-day cycle for 3 cycles)
Study: 20798939
Drug: Dexamethasone (total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (total dose of 45 mg, with 15 mg before docetaxel infusion and 30 mg before CYP3A assessment)
Study: 20798939
Drug: Midazolam (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (7.5 mg oral)
Study: 20809967
Drug: Neostigmine 70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 70 μg/kg with glycopyrrolate 14 μg/kg
Study: 20811392
Drug: STA-21 ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: STA-21 ointment
Study: 20812791
Drug: Antipsychotic medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic medications (study drug)
Study: 20812791
Drug: Previous antipsychotic
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Previous antipsychotic medication (used prior to enrollment)
Study: 20812850
Drug: Quadrivalent HPV
Normalized name: HPV, quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent HPV vaccine (types 6, 11, 16, and 18), administered 0.5 mL intramuscularly at entry, week 8, and week 24.
Study: 20814317
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR (150-300 mg/d)
Study: 20815703
Drug: Blocking antibodies
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blocking antibodies (measured by HBGA blocking assay)
Study: 20816019
Drug: Dendritic cell
Normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dendritic cell based cancer vaccine (MelCancerVac)
Study: 20816040
Drug: Second-generation antipsychotics
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation antipsychotics (SGAs) followed by lamotrigine monotherapy
Study: 20816873
Drug: Sustained ventricular
Normalized name: DRESSING,VENTRICULAR ASSIST DEVICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained ventricular arrhythmia (VA) with appropriate ICD therapies
Study: 20819968
Drug: Aerobic interval
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic interval training (4 x 4 minutes at 90% of maximal heart rate, 40 minutes total, twice per week for 13 weeks)
Study: 20822542
Drug: Infliximab 3
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 3 mg/kg + methotrexate (MTX)
Study: 20822542
Drug: Infliximab 3
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 3 mg/kg + MTX
Study: 20823423
Drug: Bortezomib-doxorubicin-dexamethasone (BDD)
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib-doxorubicin-dexamethasone (BDD) therapy
Study: 20823436
Drug: 2 +
Normalized name: dHER2 + AS15 ASCI
DrugBank: SB719125 (DB16753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 + 1 doses of PCV-7 at 2, 4, and 11 months
Study: 20831796
Drug: Trazodone (50-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone (50-300 mg/day)
Study: 20837883
Drug: LCI699 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCI699 (0.5 mg BID)
Study: 20837883
Drug: LCI699 (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCI699 (1.0 mg BID)
Study: 20837883
Drug: LCI699 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCI699 (4 weeks treatment)
Study: 20837940
Drug: Temsirolimus 25-mg
Normalized name: temsirolimus 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temsirolimus 25-mg weekly (Group A)
Study: 20837940
Drug: Temsirolimus 25-mg
Normalized name: temsirolimus 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temsirolimus 25-mg weekly (Group B)
Study: 20837940
Drug: Temsirolimus 25-mg
Normalized name: temsirolimus 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temsirolimus 25-mg weekly (Group C)
Study: 20838998
Drug: Motesanib 125
Normalized name: Motesanib
DrugBank: Motesanib (DB05575)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motesanib 125 mg orally once daily for 48 weeks
Study: 20840760
Drug: CNI-free combination
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNI-free combination therapy (basiliximab, MMF, steroids and delayed Sirolimus)
Study: 20841416
Drug: Propofol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (50 μg/kg/min)
Study: 20841509
Drug: Low-dose rituximab
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rituximab plus alemtuzumab (10 mg of alemtuzumab subcutaneously on days 1 to 3, plus 100 mg of rituximab intravenously weekly in 4 doses)
Study: 20843246
Drug: INCB018424 (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB018424 (15 mg twice daily, individualized dose titration)
Study: 20843592
Drug: Thujone-free wormwood
Normalized name: Wormwood
DrugBank: Wormwood (DB14291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thujone-free wormwood preparation (1.8 g/d for 6 months)
Study: 20844233
Drug: Eltrombopag 50
Normalized name: eltrombopag 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag 50 mg orally per day for 3 weeks
Study: 20846606
Drug: Systolic and
Normalized name: Bystolic
DrugBank: Nebivolol (DB04861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systolic and diastolic deformation indexes (E(cc) and E(cc)/s)
Study: 20851682
Drug: Pazopanib (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib (800 mg daily in 4-week cycles)
Study: 20854181
Drug: H1-Coil repetitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1-Coil repetitive transcranial magnetic stimulation (rTMS) at 20 Hz, 2 s on, 20 s off, totaling 1680 stimuli, daily for four weeks
Study: 20854821
Drug: S-adenosyl methionine
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-adenosyl methionine (SAMe) 1600 mg daily for 2 weeks followed by peginterferon and ribavirin for 48 weeks
Study: 20855799
Drug: darunavir-ritonavir, 600/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: darunavir-ritonavir, 600/100 mg twice daily, plus an investigator-selected optimized background regimen
Study: 20859150
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid 3.9 g/d for up to 5 days per menstrual cycle through six cycles
Study: 20860020
Drug: Darifenacin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darifenacin treatment
Study: 20862748
Drug: Sunitinib 50
Normalized name: sunitinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 50 mg orally, once daily, on Schedule 4/2
Study: 20863431
Drug: octagam 10%
Normalized name: Octagam 10% Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: octagam 10% 1 g/kg/day on two consecutive days; maximum infusion rate of 0·12 ml/kg/minute
Study: 20874827
Drug: Peptide LY6K-177,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptide LY6K-177, peptide TTK-567, and CpG-7909 (level-1; 0, level-2; 0.02, level-3; 0.1 mg/kg)
Study: 20875102
Drug: IDD-3 (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDD-3 (8 doses of autologous monocyte-derived matured DC with GM-CSF and IL-13, pulsed with melanoma cell line lysates, matured with interferon gamma)
Study: 20879880
Drug: Reduced chemotherapy
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced chemotherapy (4 cycles for favorable features, 8 cycles for unfavorable features)
Study: 20879880
Drug: Reduced chemotherapy
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced chemotherapy
Study: 20881954
Drug: S-warfarin (CYP2C9
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-warfarin (CYP2C9 specific) with pazopanib
Study: 20883227
Drug: Carvedilol CR
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol CR 80 mg + Lisinopril 40 mg
Study: 20883227
Drug: Carvedilol CR
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol CR 80 mg + Lisinopril 20 mg
Study: 20883227
Drug: Carvedilol CR
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol CR 80 mg + Lisinopril 10 mg
Study: 20883227
Drug: Carvedilol CR
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol CR 40 mg + Lisinopril 40 mg
Study: 20883227
Drug: Carvedilol CR
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol CR 20 mg + Lisinopril 40 mg
Study: 20883227
Drug: Carvedilol CR
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol CR 20 mg + Lisinopril 20 mg
Study: 20883227
Drug: Carvedilol CR
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol CR 40 mg + Lisinopril 20 mg
Study: 20883227
Drug: Carvedilol CR
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol CR 40 mg + Lisinopril 10 mg
Study: 20883227
Drug: Carvedilol CR
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol CR 20 mg + Lisinopril 10 mg
Study: 20883929
Drug: High-dose dobutamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dobutamine stress MRI
Study: 20885982
Drug: OCD-like behaviours
Normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCD-like behaviours correlated with higher scores of complex tics, neuroleptic and SSRIs treatment frequency, and less successful socio-professional adaptation.
Study: 20886200
Drug: Long-acting bronchodilator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting bronchodilator (LABD) monotherapy
Study: 20888065
Drug: PF-3512676 (0.08,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-3512676 (0.08, 0.16, 0.24, 0.28, 0.32, or 0.36 mg/kg) administered as 24 weekly subcutaneous injections
Study: 20888102
Drug: Once-daily extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily extended-release niacin
Study: 20890189
Drug: Daptomycin at
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daptomycin at 8 mg/kg intravenously over 30 mins
Study: 20890189
Drug: Daptomycin at
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daptomycin at 8 mg/kg every 48 hrs
Study: 20919852
Drug: Busulfan AUC
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulfan AUC of 5800 µmol-min/L
Study: 20919852
Drug: Busulfan AUC
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulfan AUC of 6800 µmol-min/L
Study: 20919852
Drug: Busulfan test
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulfan test dose
Study: 20919852
Drug: Busulfan conditioning
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulfan conditioning dose 1 pharmacokinetics
Study: 20920156
Drug: Rotigotine transdermal
Normalized name: Rotigotine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine transdermal patch (0.5 mg/24 h to 4 mg/24 h, mean daily dose 2.93 ± 1.14 mg/24 h after 2 years)
Study: 20920370
Drug: IV alpha-1
Normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV alpha-1 antitrypsin (AAT) augmentation therapy (Alfalastin® or Prolastin®)
Study: 20920778
Drug: IL-4/IL-13 antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-4/IL-13 antagonist
Study: 20921437
Drug: Upgrades to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upgrades to or revised cardiac resynchronization therapy device (cohort 2)
Study: 20921906
Drug: Deferiprone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferiprone (50 to 100 mg/kg/d)
Study: 20922800
Drug: Apricoxib 400
Normalized name: Apricoxib
DrugBank: Apricoxib (DB12378)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apricoxib 400 mg/day plus erlotinib 150 mg/day
Study: 20922800
Drug: Apricoxib 100
Normalized name: Apricoxib
DrugBank: Apricoxib (DB12378)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apricoxib 100 mg/day
Study: 20922800
Drug: Apricoxib 200
Normalized name: Apricoxib
DrugBank: Apricoxib (DB12378)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apricoxib 200 mg/day
Study: 20922800
Drug: Apricoxib 400
Normalized name: Apricoxib
DrugBank: Apricoxib (DB12378)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apricoxib 400 mg/day
Study: 20922800
Drug: Prior EGFR-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior EGFR-directed therapies
Study: 20923256
Drug: PTH(1-84) 100
Normalized name: PTH
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PTH(1-84) 100 µg once daily for 36 months
Study: 20923544
Drug: Apatinib (YN968D1)
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib (YN968D1) 850 mg once daily
Study: 20923544
Drug: Apatinib (YN968D1)
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib (YN968D1) 750 mg once daily
Study: 20923561
Drug: CKD patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CKD patients with e-GFR ≤ 90 ml/min (Group 2)
Study: 20923561
Drug: CKD patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CKD patients with 60 ml/min ≤ e-GFR < 90 ml/min (Group 3)
Study: 20923561
Drug: CKD patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CKD patients with 15 ml/min ≤ e-GFR < 60 ml/min (Group 4)
Study: 20923629
Drug: Minocycline augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline augmentation of pharmacotherapy
Study: 20924570
Drug: Vaginal suppository
Normalized name: Vaginal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal suppository containing 1,200 mg miconazole
Study: 20925950
Drug: Dihydrocapsiate (DCT)
Normalized name: dihydrocapsaicin
DrugBank: Dihydrocapsiate (DB15398)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydrocapsiate (DCT) 9 mg/day
Study: 20925950
Drug: Dihydrocapsiate (DCT)
Normalized name: dihydrocapsaicin
DrugBank: Dihydrocapsiate (DB15398)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydrocapsiate (DCT) 3 mg/day
Study: 20926537
Drug: Hormonal interventions
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal interventions (specific hormones not detailed)
Study: 20926818
Drug: Microperimetry treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microperimetry treatment (one eye randomized to treatment)
Study: 20930086
Drug: Autologous MSC
Normalized name: AUTOLOGOUS MSC-NTF
DrugBank: Debamestrocel (DB17934)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous MSC infusion
Study: 20930628
Drug: IDO inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDO inhibitors (oral administration)
Study: 20932222
Drug: Duloxetine 30
Normalized name: duloxetine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 30 mg to 120 mg daily
Study: 20934233
Drug: Irinotecan (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan (150 mg/m(2))/oxaliplatin (85 mg/m(2)) followed by etoposide (100 mg/m(2)×3)/carboplatin (AUC 6)
Study: 20935227
Drug: Resveratrol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol 0.5 g daily for 29 days
Study: 20935227
Drug: Resveratrol 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol 1.0 g daily for 29 days
Study: 20935227
Drug: Resveratrol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol 2.5 g daily for 29 days
Study: 20935227
Drug: Resveratrol 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol 5.0 g daily for 29 days
Study: 20937945
Drug: Intrathecal and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal and intravenous administration of autologous mesenchymal stem cells (MSCs). Mean (SD) of 63.2 × 10(6) (2.5 × 10(6)) MSCs injected. Follow-up ≤25 months.
Study: 20938098
Drug: 3-month dual
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-month dual antiplatelet therapy (aspirin 100-200mg + clopidogrel 75 mg daily)
Study: 20943702
Drug: Waist circumference,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waist circumference, BMI, blood pressure, plasma glucose, insulin, HOMA-IR
Study: 20946651
Drug: Personal Concerns
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personal Concerns Inventory interview plus treatment as usual
Study: 20947286
Drug: Varenicline 1
Normalized name: varenicline 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline 1 mg twice daily with 12 weeks of behavioral counseling
Study: 20950306
Drug: Bicalutamide (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide (150 mg) monotherapy
Study: 20952514
Drug: Bortezomib 1
Normalized name: bortezomib 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib 1 mg/m2
Study: 20952517
Drug: Liposomal cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal cytarabine (50 mg) given intrathecally together with systemic or intrathecal dexamethasone once every 2 weeks
Study: 20952687
Drug: UCB Treg
Normalized name: Col-Treg
DrugBank: Col-Treg (DB18451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UCB Treg infusion (0.1-30 × 10(5) UCB Treg/kg)
Study: 20955442
Drug: Adalimumab (160/80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (160/80 mg at weeks 0/2 for induction, 40 mg every other week for maintenance)
Study: 20955619
Drug: E. coli
Normalized name: E. coli antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: E. coli RNA fragments (20, 40, or 60 mg starting dose, escalated to a maximum of 80 mg)
Study: 20955619
Drug: Yeast RNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yeast RNA fragments (20, 40, or 60 mg starting dose, escalated to a maximum of 80 mg)
Study: 20955619
Drug: E. coli
Normalized name: E. coli antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: E. coli RNA fragments (60 and 80 mg doses)
Study: 20956472
Drug: sorafenib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: sorafenib (400 mg orally twice a day)
Study: 20956472
Drug: non-neoadjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-neoadjuvant treatment
Study: 20958975
Drug: Benzodiazepines as
Normalized name: 1,3-dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one
DrugBank: Nitrazepam (DB01595)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzodiazepines as adjuvant therapy
Study: 20961630
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of bone marrow-derived stem cells
Study: 20961818
Drug: AquADEKs® softgels
Approvals — FDA: no, EMA: no, PMDA: no
Description: AquADEKs® softgels daily for 12 weeks
Study: 20961907
Drug: Antiviral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral treatment (specifics not provided)
Study: 20961907
Drug: Antilymphocyte antibody
Normalized name: antilymphocyte immunoglobulin
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antilymphocyte antibody administration
Study: 20962148
Drug: 25 μg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 μg/d cholecalciferol supplementation for 4 weeks
Study: 20962148
Drug: Controlled intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled intake providing 5 μg vitamin D and 1117 mg Ca/d
Study: 20964499
Drug: Amisulpride (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride (400 mg/day)
Study: 20966039
Drug: Oxygen treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen treatment for symptomatic familial pulmonary fibrosis
Study: 20967484
Drug: UCN-01 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UCN-01 at 90 mg/m² over 3 h on cycle 1, reduced to 45 mg/m² over 3 h for subsequent cycles, every 21 days
Study: 20978276
Drug: Marqibo (vincristine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marqibo (vincristine sulfate liposome injection, VSLI)
Study: 20979469
Drug: Crizotinib (PF-02341066)
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Crizotinib (PF-02341066) at a dose of 250 mg twice daily in 28-day cycles
Study: 20980795
Drug: AS03(A)-adjuvanted H1N1
Normalized name: AS03 Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03(A)-adjuvanted H1N1 2009 pandemic vaccine (3.75 μg HA) after Dose 1
Study: 20980795
Drug: AS03(A)-adjuvanted H1N1
Normalized name: AS03 Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03(A)-adjuvanted H1N1 2009 pandemic vaccine (3.75 μg HA) after Dose 2
Study: 20980795
Drug: AS03(A)-adjuvanted H1N1
Normalized name: AS03 Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03(A)-adjuvanted H1N1 2009 pandemic vaccine (3.75 μg HA)
Study: 20980933
Drug: 10-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-valent pneumococcal conjugate vaccine (PHiD-CV)
Study: 20980933
Drug: DTPw-HBV/Hib and
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPw-HBV/Hib and poliovirus vaccines
Study: 20981545
Drug: 3-aminopyridine-2-carboxaldehydethiosemicarbazone (3-AP)
Normalized name: γ-Aminopyridine
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-aminopyridine-2-carboxaldehydethiosemicarbazone (3-AP) plus gemcitabine (1,000 mg/m2 on days 1, 8, and 15 every 28 days)